Expression of Transforming Growth Factor -beta1, -beta2 in Human Endometrium of The Uterine Adenocarcinoma

This study examined how transforming growth factor (TGF)-beta1 and TGF-beta2 are expressed across different endometrial states, comparing normal menstrual-cycle phases and menopausal endometrium to endometrial hyperplasia and adenocarcinoma after hysterectomy. Using immunohistochemical staining with antibodies against TGF-beta1/ beta2 in 50 patients (divided into proliferative, secretory, menopausal, hyperplasia, and adenocarcinoma groups), the authors scored staining intensity as absent/trace/weak/moderate/intense based on color development thresholds. They found higher glandular expression of both TGF-beta1 (noted higher in secretory versus hyperplasia/adenocarcinoma) and TGF-beta2 (generally higher in normal cycle/menopausal samples), with little to no specific differences between stromal, vascular, and myometrial compartments, and similar expression patterns between hyperplasia and adenocarcinoma. The paper concludes that TGF-beta1 and TGF-beta2 may play roles in suppressing precancerous or cancerous development in endometrial glandular cells, and it does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works